About avatrombopag
Thrombopoietin receptor agonist
Used for
- Treats low platelet counts in adults with chronic liver disease before a planned procedure.
- Treats chronic immune thrombocytopenia in adults with insufficient response to previous treatment.
Usual adult dose
Chronic liver disease: 40 or 60 mg once daily for 5 days, based on platelet count. Immune thrombocytopenia: usually 20 mg once daily, adjusted to maintain platelet counts.
Common side effects
- Headache
- Tiredness
- Nausea
- Blood clots
Important warnings
- Can increase the risk of blood clots; monitor platelet counts.
- Do not use to normalise platelet counts.
- In chronic liver disease, take for 5 days starting 10–13 days before a procedure.
- Dose changes may be needed with liver problems or interacting medicines.
Pregnancy
Human pregnancy information is limited; use only when clearly needed. Discuss potential risks with a healthcare professional.
Breastfeeding
It is unknown whether avatrombopag passes into breast milk. Breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
Interactions
- Strong or moderate CYP2C9 or CYP3A4 inhibitors can increase avatrombopag levels.
- Strong or moderate CYP2C9 or CYP3A4 inducers can reduce avatrombopag levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.